Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 4/20 | 0.47 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | ARG1 | P05089 | 1/20 | 0.44 |
| ▸ | ARG2 | P78540 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2313955 | 1.00 | NOS2 (0.47) | NOS2NOS1NOS3CPB2SLC1A3 | |
| SCHEMBL8498221 | 1.00 | NOS2 (0.47) | NOS2NOS1NOS3CPB2SLC1A3 | |
| SCHEMBL28090084 | 0.98 | NOS2 (0.46) | NOS2NOS1NOS3CPB2SLC1A3 | |
| Hydrochloric Acid SCHEMBL6837836 | 0.98 | NOS2 (0.46) | NOS2NOS1NOS3CPB2SLC1A3 | |
| Hydrochloric Acid SCHEMBL6837838 | 0.98 | NOS2 (0.46) | NOS2NOS1NOS3CPB2SLC1A3 | |
| Cysteine SCHEMBL14775442 | 0.90 | PTGS1 (0.61) | NOS2NOS1NOS3CPB2SLC1A3 | |
| Cysteine SCHEMBL14775438 | 0.90 | PTGS1 (0.61) | NOS2NOS1NOS3CPB2SLC1A3 | |
| SCHEMBL13525040 | 0.83 | CPB2 (0.40) | NOS2NOS1NOS3CPB2SLC1A3 | |
| SCHEMBL13435232 | 0.83 | CPB2 (0.40) | NOS2NOS1NOS3CPB2SLC1A3 | |
| SCHEMBL8235081 | 0.82 | NOS2 (0.44) | NOS2NOS1NOS3SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034277-A1 | SYSTEMS AND METHODS FOR PATHOGEN INACTIVATION OF BLOOD PRODUCTS | CERUS CORP (US) | 2026-02-05 | — | — | US | claimed |
| EP-4551948-A2 | COMPOSITIONS AND METHODS FOR POLYPEPTIDE ANALYSIS | Quantum-Si Incorporated (US) | 2025-05-14 | — | — | EP | claimed |
| CN-119998660-A | Compositions and methods for polypeptide analysis | 宽腾矽公司 | 2025-05-13 | — | — | CN | claimed |
| WO-2025026226-A1 | POLYETHYLENE GLYCOL SMALL MOLECULE DRUG, PREPARATION METHOD THEREFOR AND USE THEREOF | 重庆阿普格雷生物科技有限公司 | 2025-02-06 | — | — | WO | claimed |
| CN-117867481-A | High-stability cyanide-free electroless reduced gold plating solution | 江苏矽智半导体科技有限公司 | 2024-04-12 | — | — | CN | claimed |
| WO-2024031031-A2 | COMPOSITIONS AND METHODS FOR POLYPEPTIDE ANALYSIS | Quantum-Si Incorporated (US) | 2024-02-08 | — | — | WO | claimed |
| US-20230263833-A1 | COMPOSITIONS AND METHODS FOR PREPARATION OF RED BLOOD CELLS | CERUS CORPORATION | 2023-08-24 | — | — | US | claimed |
| WO-2021253105-A1 | AGRICULTURAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF BACTERIAL DISEASES AND DISORDERS | Amazon AgroSciences LTDA (BR) | 2021-12-23 | — | — | WO | claimed |
| EP-2285210-B1 | METHOD FOR REDUCING DEHYDRATION IN A RED BLOOD CELL COMPOSITION | CERUS CORP (US) | 2017-05-17 | — | — | EP | claimed |
| EP-1874948-B1 | Process for the production of y-glutamylcysteine | NEWSOUTH INNOVATIONS PTY LTD (AU) | 2013-03-20 | — | — | EP | claimed |
| US-8236533-B2 | Process for the production of γ-glutamylcysteine | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2012-08-07 | — | — | US | claimed |
| US-20090136993-A1 | Process for the Production of Gamma-Glutamylcysteine | NEWSOUTH INNOVATIONS PTY LIMITED | 2009-05-28 | — | — | US | claimed |
| EP-1874948-A1 | PROCESS FOR THE PRODUCTION OF y-GLUTAMYLCYSTEINE | Newsouth Innovations Pty Limited (AU) | 2008-01-09 | — | — | EP | claimed |
| WO-2006102722-A1 | PROCESS FOR THE PRODUCTION OF Ϝ-GLUTAMYLCYSTEINE | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2006-10-05 | — | — | WO | claimed |
| CN-1424900-A | Topical skin composition | TONDAR COMMERCIAL GROUP INTERN (US) | 2003-06-18 | — | — | CN | claimed |
| US-20030095959-A1 | Topical skin composition | ACCESS BUSINESS GROUP INTERNATIONAL LLC. | 2003-05-22 | — | — | US | claimed |
| US-5728373-A | EXHIBITING DEEP SKIN PENETRATION | BEIERSDORF AG (DE) | 1998-03-17 | — | — | US | claimed |
| EP-0656774-B1 | COSMETIC AND DERMATOLOGICAL SUNSCREEN COMPOSITIONS CONTAINING THIOLS AND/OR THIOL DERIVATES | BEIERSDORF AG (DE) | 1997-01-22 | — | — | EP | claimed |
| EP-0138262-B1 | COMPOSITION FOR TREATMENT OF SKIN AFFECTIONS AND ITS APPLICATION | Chemisch Adviesbureau Drs. J.C.P. Schreuder B.V. (NL) | 1990-06-13 | — | — | EP | claimed |
| EP-0138262-A2 | Composition for treatment of skin affections and its application | Chemisch Adviesbureau Drs. J.C.P. Schreuder B.V. (NL) | 1985-04-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034277-A1 | SYSTEMS AND METHODS FOR PATHOGEN INACTIVATION OF BLOOD PRODUCTS | PRF1, CFD, F5 | NOS2 227/4885NOS1 229/4885NOS3 264/4885 |
| US-20030095959-A1 | Topical skin composition | CUTA, S100A4, KRT18 | NOS2 77/4885NOS1 96/4885NOS3 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.